Longitudinal Evaluation of [18-F]MK-6240 as a Novel Tau PET Radiotracer in Patients With Alzheimer's Disease Dementia or Mild Cognitive Impairment Compared to Healthy Volunteers
Latest Information Update: 07 Aug 2023
Price :
$35 *
At a glance
- Drugs Florquinitau F18 (Primary)
- Indications Alzheimer's disease; Mild cognitive impairment
- Focus Diagnostic use
- 14 Jul 2022 Status changed from recruiting to completed.
- 14 May 2021 Planned End Date changed from 1 Sep 2022 to 1 Dec 2022.
- 14 May 2021 Planned primary completion date changed from 1 Mar 2022 to 1 Jul 2022.